Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11605844 | 0.92 | PKM (0.63) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL265611 | 0.89 | PKM (0.61) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL12169347 | 0.86 | PKM (0.65) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3971438 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 0.86 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-1446401-B1 | C5-modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1446401-A4 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | MASTALERZ HAROLD | 2005-09-22 | — | — | US | disclosed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| EP-1446401-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | disclosed |
| WO-2003042172-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | PKM 3605/4885HTT 3603/4885ALDH1A1 2091/4885 |
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | PKM 3494/4885HTT 2457/4885ALDH1A1 836/4885 |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | PKM 3571/4885HTT 3420/4885ALDH1A1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.